Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Update

Avalon GloboCare Corp. (NASDAQ:ALBT) was the recipient of a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 22,400 shares, a decline of 80.4% from the December 31st total of 114,200 shares. Based on an average daily volume of 1,430,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 5.3% of the company’s shares are sold short.

Avalon GloboCare Stock Down 0.3 %

ALBT opened at $3.38 on Wednesday. Avalon GloboCare has a 52-week low of $2.11 and a 52-week high of $21.60. The company has a 50 day moving average of $3.43 and a two-hundred day moving average of $3.84. The company has a market cap of $3.68 million, a P/E ratio of -0.17 and a beta of 0.19.

Avalon GloboCare (NASDAQ:ALBT) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.82) earnings per share (EPS) for the quarter. The firm had revenue of $0.35 million for the quarter.

About Avalon GloboCare

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.